Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 11OTHER 6NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 4Sarcoma, Alveolar Soft Part 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Glioblastoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1Rhabdoid Tumor 1Recurrent Bladder Urothelial Carcinoma 1Papillary renal cell carcinoma, sporadic 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Mesothelioma, Malignant 1

Interventions

Cisplatin 18Brachytherapy 14Radiotherapy 11Platinum 91,2-diaminocyclohexaneplatinum II citrate 9Radiation 7Paclitaxel 7aldesleukin 6Specimen Handling 6fludarabine phosphate 5fludarabine 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5Colposcopy 5Topotecan 4Immunoglobulin G 4Human Papillomavirus DNA Tests 4Fluorodeoxyglucose F18 4Disulfides 4Biopsy 4Bevacizumab 43-aminopyridine-2-carboxaldehyde thiosemicarbazone 4Trastuzumab 3Taxes 3Nivolumab 3Ipilimumab 3Congresses as Topic 3Carboplatin 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Uterine Cervical Neoplasms × atezolizumab × Clear all
NCT03738228 2025-11-12

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled 17 charts
Gynecologic

Uterine Cervical Neoplasms

NCT02921269 2023-02-21

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
11 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡